Studies have found that obese mice also showed a significantly better response to anti-PD-1 without significant toxic side effects [130], which was reproduced in multiple cancer populations receiving ICIs [131], with higher body mass index (BMI) (BMI > 30) patients showing reduction in tumor burden and improvement in PFS and OS. The gene discussed is PDCD1; the disease is cancer.